A number of other research analysts also recently weighed in on CRSP. Needham & Company LLC reissued a “buy” rating and issued a $84.00 target price on shares of Crispr Therapeutics in a report on Monday, December 23rd. Wells Fargo & Co reissued a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. ValuEngine raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Finally, Canaccord Genuity raised their price objective on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $71.38.
CRSP stock opened at $60.91 on Wednesday. Crispr Therapeutics has a fifty-two week low of $27.11 and a fifty-two week high of $74.00. The business’s 50-day moving average is $65.68 and its two-hundred day moving average is $50.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The company has a market cap of $3.64 billion, a price-to-earnings ratio of -17.70 and a beta of 3.30.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The company had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. Equities analysts predict that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $390,000. The disclosure for this sale can be found here. Insiders sold 56,118 shares of company stock worth $3,620,760 in the last ninety days. Corporate insiders own 21.40% of the company’s stock.
Several large investors have recently added to or reduced their stakes in CRSP. NEXT Financial Group Inc grew its position in shares of Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after purchasing an additional 549 shares in the last quarter. Coastal Investment Advisors Inc. purchased a new stake in shares of Crispr Therapeutics during the third quarter worth about $26,000. US Bancorp DE grew its position in shares of Crispr Therapeutics by 553.7% during the second quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after purchasing an additional 526 shares in the last quarter. BSW Wealth Partners purchased a new stake in shares of Crispr Therapeutics during the second quarter worth about $39,000. Finally, BNP Paribas Arbitrage SA purchased a new stake in shares of Crispr Therapeutics during the second quarter worth about $41,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Why do earnings reports matter?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.